NEWS
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
MediciNova, Inc. (NASDAQ:MNOV) has announced that an abstract regarding the COMBAT-ALS clinical trial of MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis (ALS) treatment has been accepted for poster presentation at the 35th International Symposium on ALS / MND. The symposium will take place from December 6-8, 2024, in Montreal, Canada.
The presentation, titled 'COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Interim Analysis Results', will be delivered by lead Principal Investigator Dr. Björn Oskarsson, Associate Professor of Neurology and Director of ALS Center of Excellence at Jacksonville, FL. The abstract has been assigned Paper Number 302 and falls under the theme of Clinical Trial and Trial Design.
The presentation, titled 'COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Interim Analysis Results', will be delivered by lead Principal Investigator Dr. Björn Oskarsson, Associate Professor of Neurology and Director of ALS Center of Excellence at Jacksonville, FL. The abstract has been assigned Paper Number 302 and falls under the theme of Clinical Trial and Trial Design.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment